Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

News Walgreens Boots Alliance is considering the sale of its Shields Health Solutions specialty pharmacy business would mean unloading a lucrative operation with huge growth potential.

Why A Walgreens Sale Of Shields Specialty Pharmacy Makes Little Sense

Walgreens Boots Alliance is exploring a sale of specialty pharmacy company Shields Health Solutions, Bloomberg News reported on Tuesday, citing people familiar with the matter.

Walgreens to explore sale of Shields Health for over $4 bln - Bloomberg News

A key component of income investing is a portfolio that includes safe dividends, those that are unlikely to shrink or disappear.

Is Walgreens Stock's Dividend Safe Now?

Every day for the next three weeks, we're going to highlight one of Schaeffer's top 12 picks for 2024.

Top Stock Picks for 2024: Walgreens Boots Alliance

Walgreens cut its dividend this year, ending a multi-decade run of increases. 3M's payout could face a similar fate.

Will 3M's High-Yielding Dividend Face the Same Fate as Walgreens' Once-Mighty Payout?

Chevron

Nucor

Steel Dynamics

Stanley Black & Decker

Dividend cuts and increases, and even no dividend change at all, can provide valuable information to investors. Walgreens' dividend cut was hinted at in mid-2023, while companies like Nucor, Steel Dynamics, Chevron, and Stanley Black & Decker have all told more positive stories in recent years.

This Is Why You Should Pay Close Attention to Dividend Increases

Walgreens Boots Alliance reported a decline in gross profit and an operating loss in its fiscal first quarter earnings. The company's cash flow has been in freefall, leading to a dividend cut. Despite the uncertainties, investors can consider selling $20 strike price put options to earn income and set a lower entry point.

Walgreens Boots Alliance: Income Opportunity After Dividend Cut

Tesla

Albemarle

Boeing

Charles River Laboratories

Enphase Energy

Etsy

Norwegian Cruise Line

ON Semiconductor

V.F.

The S&P 500 index is up slightly in 2024, but many components are big losers, including Dow Jones giant Boeing and Tesla.

Ten Big Losers To Start The Year. Tesla Isn't The Worst.

Walgreens Boots Allicance Inc. (WBA, Financial) recently completed a leadership transition with a new CEO. One of his first acts was to cut the dividend by 48%.

Is a Turnaround Ahead for Walgreens?

Casey's General Stores

FedEx

3 Large-Cap Stocks Seeing Insider Activity

CVS Health

Rite Aid Corp

A spate of pharmacy closings in Boston have drawn protests as more than 1,000 drug store chain locations across the country have closed, reigniting long standing concerns that low-income, Black and Latino Americans are bearing the brunt as pharmacies continue to disappear amid increased competition and other factors.

Here's Why Drug Stores Are Closing In Minority Neighborhoods: Walgreens, CVS And Rite Aid Shutter More Than 1,000

Intel

Boeing is dealing with another PR nightmare. Walgreens cut its dividend in half.

Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks So Far in 2024?

Dow Inc

Innovative Industrial Properties

Johnson & Johnson

Pfizer

PennantPark Investment

For inventors looking for a financial compass to navigate the sea of investments, here is the realm of the “Dividend Dynasty.” Here, seven high-yield stocks stand as pillars of long-term wealth accumulation.

Dividend Dynasty: 7 High-Yield Stocks for Long-Term Wealth Accumulation

Genuine Parts

Orion Office REIT

Despite how strong the stock market grew in 2023, there were more than a few pockets of despair in the market. We know the S&P 500 was driven higher almost wholly on the strength of the Magnificent 7 stocks, but the Dow Jones Industrial Average and Nasdaq 100 also experienced superb gains.

Can My Portfolio's 3 Worst Stocks From 2023 Rebound in 2024?

Bristol-Myers

Altria

Virtus InfraCap U.S. Preferred Stock ETF

Verizon

The markets had a rough start to the year, with the S&P 500 and Nasdaq declining in the first week of January.

Dividend Harvesting Portfolio Week 149: $14,900 Allocated, $1,316.50 In Projected Dividends

A dividend is only reliable if a company is growing earnings. Walmart and Apple have low yields but are excellent businesses that regularly raise their dividends.

Walgreens Cut Its Dividend by 48%: Here Are 5 Better Dow Dividend Stocks to Buy in January

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Cincinnati Financial

Federal Realty Investment Trust

Coca-Cola

NextEra Energy

Realty Income Corp

PepsiCo

T. Rowe Price Group

Exxon Mobil

"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years."--Kiplinger.com/Investing.

3 Dividend Aristocrats Signal Buy In January With 7 To Watch

We've also got an investor's look at Aritzia and Shopify.

Is Walgreens Boots Alliance on the Right Track?

Many businesses faced financial challenges in 2023, leading to cost-cutting initiatives which placed downward pressures on those paying a dividend. Walgreens recently reduced its dividend by 48%, highlighting the impact on dividend investors. Dividend cuts are bound to happen in long-term investments, but can sometimes be avoided through strategic measures.

Walgreens Q1: Dividend Cut Now What? (Rating Upgrade)

Kinder Morgan

Shell PLC

Walgreens' dividend was unsustainable. There are cases of companies cutting the dividend and benefiting over time.

This Dow Jones Stock Just Slashed Its Dividend By 48%. Here's Why It Could Benefit Investors

Apple

Costco

Procter & Gamble

Walgreens is a great example of the risks of chasing yield over dividend quality. Costco's special dividend fails to meet the needs of income investors.

The Biggest Mistake Income Investors Can Make in 2024

A high dividend yield can be a misleading investment opportunity. Year after year of sizable dividend raises can still result in a low yield if a stock is outperforming.

The Highest-Yielding Stock in the Dow Just Cut Its Dividend to Its Lowest Level in 11 Years

Walgreens reduced its dividend by 48%. It was a move that was arguably long overdue given the poor state of the pharmacy store chain's finances.

Walgreens Slashed Its Dividend, but That's a Good Thing for Investors

In an interview with CNBC's Jim Cramer, Walgreens CEO Tim Wentworth lauded the strength of the company's brand.

Walgreens CEO says company is using its stores and brand to boost health-care business

Humana

Walgreens Boots Alliance has agreed to pay $360 million to insurance company Humana to settle a lawsuit alleging the retail-pharmacy chain overcharged for prescription-drug reimbursements.

News for Walgreens Stock (WBA)